ALLIANCE PHARMA PLC

Declaration of Voting Results & Voting Rights Announcements • Sep 3, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0920L

Alliance Pharma PLC

03 September 2019

For immediate release	3 September 2019

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Total Voting Rights

Alliance Pharma plc (AIM: APH), the international healthcare group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

As at 29 August 2019 the Company's issued share capital consists of 519,490,041 Ordinary Shares of 1p each.

The total number of voting rights in the Company is 519,490,041 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information:

Alliance Pharma plc                                                                                          + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk 

Buchanan                                                                                                           + 44 (0) 20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited                                                                                 + 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield

Corporate Broking: James Black

Investec Bank plc                                                                                              +44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVREALNDEADNEFF